Investigation of Optimal Dosage Regimen for HRS9531 Tablets in Healthy Subjects

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

144

Participants

Timeline

Start Date

August 5, 2024

Primary Completion Date

November 30, 2024

Study Completion Date

November 30, 2024

Conditions

Overweight or Obese, Type 2 Diabetes

Interventions

DRUG

HRS9531 tablets

Trial Locations (1)

The affiliated hospital of Qingdao University, Qingdao

All Listed Sponsors

lead

Fujian Shengdi Pharmaceutical Co., Ltd.

INDUSTRY

NCT06506175 - Investigation of Optimal Dosage Regimen for HRS9531 Tablets in Healthy Subjects | Biotech Hunter | Biotech Hunter